trending Market Intelligence /marketintelligence/en/news-insights/trending/zfgk8p4ntovmrlmy0fbgtg2 content esgSubNav
In This List

Corcept Therapeutics plans $100M share buyback program

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes

Blog

Investment Banking Essentials Newsletter April Edition - 2022


Corcept Therapeutics plans $100M share buyback program

Corcept Therapeutics Inc. said its board approved the repurchase of up to $100 million of the company's common stock.

The Menlo Park, Calif.-based pharmaceutical company said the share buyback program will remain in effect until June 30, 2019, unless terminated earlier.

Corcept added that the timing and amount of any repurchases will be based on market conditions, stock price and other factors.